VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Taiwen Pharmaceutical Announces Positive Topline Results from China Pivotal Phase III Trial of Oral GLP-1 VCT220: Over 12% Weight Loss in One Year
Taiwen Pharmaceutical Announces Positive Topline Results from China Pivotal Phase III Trial of Oral GLP-1 VCT220: Over 12% Weight Loss in One Year
May 18, 2026 18:08 CST Updated May 19, 10:31
Share:
